Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
C4 Therapeutics reported new biomarker data showing T—cell activation from the cemsidomide Phase 1 trial and supportive preliminary Phase 1b data with elranatamab; the 75 µg combination dose was declared safe and the Phase 1b is advancing to 100 µg escalation and 75 µg expansion.Key Highlights:Orig…
Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide’s Dual Mechanism of ActionBiomarker Data from First Two Patients in Phase 1b Trial of Cemsidomide with Elranatamab Reinforce Cemsidomide’s Ability to D…
C4 Therapeutics said it presented new biomarker data from its phase 1 cemsidomide trial with dexamethasone and phase 1b trial with elranatamab at the IMS annual meeting.